Actively Recruiting
Phase IIIb Study to Characterize the Efficacy and Safety of Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
Led by Novartis Pharmaceuticals · Updated on 2026-06-08
1400
Participants Needed
217
Research Sites
54 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the combination of ribociclib and standard adjuvant endocrine therapy (ET) in adults with hormone receptor-positive, HER2-negative early breast cancer, specifically those in Anatomic Stage Group III, IIB, and some of Stage IIA. This phase IIIb, open-label, multicenter study aims to understand how this combination affects invasive breast cancer-free survival (iBCFS) in a patient population close to routine clinical practice. Participants will receive ribociclib 400 mg orally once daily on days 1 to 21 of each 28-day cycle, combined with daily ET for 36 months (about 39 cycles). ET options differ for postmenopausal women (letrozole, anastrozole, or exemestane) and for pre/perimenopausal women and men, who receive ET plus either goserelin or leuprolide injections given every 1 to 3 months. The treatment period begins with the first ribociclib dose and includes safety follow-up 30 days after the last dose. After treatment, participants will be followed up until death, withdrawal, loss to follow-up, or up to 48 months after the last participant’s first dose. During the study, participants will be regularly evaluated for breast cancer recurrence, side effects, and quality of life using various assessments such as survival rates, adverse event monitoring, and standardized questionnaires on fatigue, endocrine symptoms, and overall well-being. Safety follow-up calls will be conducted 30 days after treatment ends. This comprehensive monitoring extends up to approximately six years, ensuring detailed data collection on treatment impact and participant health throughout and after the study period.
CONDITIONS
Brief Title
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older at the time of informed consent
- Histologically or cytologically confirmed estrogen and/or progesterone receptor-positive breast cancer
- HER2-negative breast cancer defined by negative in situ hybridization or immunohistochemistry status 0, 1+, or 2+ with negative in situ hybridization if 2+
- Completed surgical resection with tumor completely removed and microscopic margins free from tumor
- Anatomic Stage Group III, IIB, or a subset of IIA early breast cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Adequate bone marrow and organ function
- QTcF interval less than 450 msec and resting heart rate between 50-99 bpm as assessed by ECG
- May have received prior endocrine therapy but enrollment within 36 months of starting prior therapy with at least 3 years remaining
- No contraindication to receive adjuvant endocrine therapy in the study
You will not qualify if you...
- Distant metastases of breast cancer beyond regional lymph nodes or evidence of recurrence after surgery
- Concurrent use of other antineoplastic therapy except adjuvant endocrine therapy
- Severe or uncontrolled medical conditions that pose unacceptable safety risks or limit life expectancy to 5 years or less
- Clinically significant uncontrolled heart disease or cardiac repolarization abnormalities
- Pregnant or breastfeeding women or women planning pregnancy during the trial
- Women of child-bearing potential not using highly effective contraception during treatment and for 21 days after
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Duration - 36 months
Participants receive ribociclib orally once daily on days 1 to 21 of a 28-day cycle, combined with daily endocrine therapy for 36 months (approximately 39 cycles).
Monthly visits for ribociclib dosing and endocrine therapy administration
Duration - Up to approximately 7 years (including treatment and follow-up)
Participants are followed starting 30 days after completing or discontinuing study treatment until death, withdrawal, loss to follow-up, or up to 48 months after the last participant's first dose.
Safety follow-up call 30 days after last treatment dose and periodic follow-up visits thereafter
Trial Site Locations
Total: 217 locations
1
Central Alabama Research
Birmingham, Alabama, United States, 35209
Actively Recruiting
2
Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States, 99508
Actively Recruiting
3
Western Reg MC-COH Phoenix
Goodyear, Arizona, United States, 85338
Actively Recruiting
4
CARTI Cancer Center
Little Rock, Arkansas, United States, 72205
Actively Recruiting
5
Beverly Hills Cancer Center
Beverly Hills, California, United States, 90211
Actively Recruiting
6
Onco Inst of Hope and Innovation
Cerritos, California, United States, 90703
Actively Recruiting
7
City of Hope National Medical
Duarte, California, United States, 91010
Actively Recruiting
8
Providence Medical Foundation
Fullerton, California, United States, 92835
Actively Recruiting
9
Palo Alto Medical Foundation
Mountain View, California, United States, 94040
Actively Recruiting
10
UC Irvine Medical Center
Orange, California, United States, 92868
Actively Recruiting
11
Sutter Inst Medical Research
Sacramento, California, United States, 95816-5199
Actively Recruiting
12
School Of Medicine
Sacramento, California, United States, 95817
Actively Recruiting
13
Rocky Mountain Cancer Centers
Denver, Colorado, United States, 80218
Actively Recruiting
14
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia, United States, 20007-2197
Actively Recruiting
15
Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010
Actively Recruiting
16
AdventHealth Altamonte Springs
Altamonte Springs, Florida, United States, 32701
Actively Recruiting
17
Holy Cross Health
Fort Lauderdale, Florida, United States, 33308
Actively Recruiting
18
Hialeah Hospital
Hialeah, Florida, United States, 33013
Actively Recruiting
19
Memorial Cancer Institute
Hollywood, Florida, United States, 33021
Actively Recruiting
20
Jupiter Medical Center
Jupiter, Florida, United States, 33458
Actively Recruiting
21
Ocala Research Institute, Inc
Ocala, Florida, United States, 34474
Actively Recruiting
22
University Cancer and Blood Center LLC
Athens, Georgia, United States, 30607
Actively Recruiting
23
Summit Cancer Care PC
Savannah, Georgia, United States, 31405
Actively Recruiting
24
Hawaii Cancer Care
Honolulu, Hawaii, United States, 96813
Actively Recruiting
25
Affiliated Oncologists IL
Chicago, Illinois, United States, 60415
Actively Recruiting
26
Hope And Healing Care
Hinsdale, Illinois, United States, 60521
Actively Recruiting
27
Midwestern Reg MC COH Chicago
Zion, Illinois, United States, 60099
Actively Recruiting
28
Investigative Clinical R of Indiana
Indianapolis, Indiana, United States, 46260
Actively Recruiting
29
University of Iowa Health Care
Waukee, Iowa, United States, 50263
Actively Recruiting
30
University of Kansas Cancer Center
Westwood, Kansas, United States, 66205
Actively Recruiting
31
Cancer Center of Kansas
Wichita, Kansas, United States, 67214-3728
Actively Recruiting
32
Willis-Knighton Cancer Center
Shreveport, Louisiana, United States, 71103
Actively Recruiting
33
Mercy Medical Center
Baltimore, Maryland, United States, 21202
Actively Recruiting
34
Maryland Oncology Hematology P A
Silver Spring, Maryland, United States, 20904
Actively Recruiting
35
Boston Medical Center
Boston, Massachusetts, United States, 02118
Actively Recruiting
36
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
37
Dana Farber Brigham Women Cancer
Milford, Massachusetts, United States, 01757
Actively Recruiting
38
Minnesota Oncology Hematology P A
Minneapolis, Minnesota, United States, 55404
Actively Recruiting
39
Allina Hlth Cancer Inst Minneapolis
Minneapolis, Minnesota, United States, 55407
Actively Recruiting
40
Jackson Oncology Associates
Jackson, Mississippi, United States, 39202
Actively Recruiting
41
HCA Midwest Division
Kansas City, Missouri, United States, 64132
Actively Recruiting
42
WA Uni School Of Med
St Louis, Missouri, United States, 63110
Actively Recruiting
43
Intermountain Healthcare
Billings, Montana, United States, 59102
Actively Recruiting
44
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68154
Actively Recruiting
45
Renown Regional Medical Center
Reno, Nevada, United States, 89502
Actively Recruiting
46
Cancer Care Specialists
Reno, Nevada, United States, 89511
Actively Recruiting
47
Summit Health
Florham Park, New Jersey, United States, 07932
Actively Recruiting
48
The Valley Hospital
Ridgewood, New Jersey, United States, 07450
Actively Recruiting
49
Presbyterian Medical Group
Albuquerque, New Mexico, United States, 87110
Actively Recruiting
50
Queens Cancer Center of Queens Hospital
Jamaica, New York, United States, 11432
Actively Recruiting
51
Optum Health
Lake Success, New York, United States, 11042
Actively Recruiting
52
Mount Sinai School of Medicine
New York, New York, United States, 10029
Actively Recruiting
53
Duke Cancer Network
Durham, North Carolina, United States, 27710
Actively Recruiting
54
Cone Health Cancer Center
Greensboro, North Carolina, United States, 27403
Actively Recruiting
55
Sanford Research USD Fargo
Fargo, North Dakota, United States, 58122
Actively Recruiting
56
Good Samaritan Regional Medical Center
Corvallis, Oregon, United States, 97330
Actively Recruiting
57
Oncology Associates of Oregon PC
Eugene, Oregon, United States, 97401-8122
Actively Recruiting
58
Northwest Cancer Specialists
Portland, Oregon, United States, 97210
Actively Recruiting
59
Oregon Oncology Specialists Salem
Salem, Oregon, United States, 97301
Actively Recruiting
60
Consultants In Med Onco And Hema
Drexel Hill, Pennsylvania, United States, 19026
Actively Recruiting
61
Univ of Pittsburg Med Ctr Pinnacle
Harrisburg, Pennsylvania, United States, 17109
Actively Recruiting
62
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Actively Recruiting
63
Bon Secours St Francis Cancer Center
Greenville, South Carolina, United States, 29607
Actively Recruiting
64
Lexington Medical Center
West Columbia, South Carolina, United States, 29169
Actively Recruiting
65
Regional Medical Oncology NC
Wilson, South Carolina, United States, 27893
Actively Recruiting
66
Sanford USD Medical Center
Sioux Falls, South Dakota, United States, 57104
Actively Recruiting
67
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
68
El Paso Texas Oncology
El Paso, Texas, United States, 79902
Actively Recruiting
69
Kelsey Seybold Clinic
Houston, Texas, United States, 77025
Actively Recruiting
70
University of Texas
Houston, Texas, United States, 77030-4099
Actively Recruiting
71
Texas Oncology P A Plano East
Plano, Texas, United States, 75075
Actively Recruiting
72
Texas Oncology PA Tyler
Tyler, Texas, United States, 75702
Actively Recruiting
73
Bon Secours Virginia Health System
Midlothian, Virginia, United States, 23114
Actively Recruiting
74
Virginia Oncology Associates
Norfolk, Virginia, United States, 23502
Actively Recruiting
75
Kadlec Clinic Hematology and Onco
Kennewick, Washington, United States, 99336
Actively Recruiting
76
Providence Regional Cancer System
Lacey, Washington, United States, 98503
Actively Recruiting
77
Valley Medical Center Research
Renton, Washington, United States, 98055
Actively Recruiting
78
Northwest Medical Specialties
Tacoma, Washington, United States, 98405
Actively Recruiting
79
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1426ANZ
Actively Recruiting
80
Novartis Investigative Site
La Plata, Buenos Aires, Argentina, B1902CMV
Actively Recruiting
81
Novartis Investigative Site
Córdoba, Argentina, X5004BAL
Actively Recruiting
82
Novartis Investigative Site
Gateshead, New South Wales, Australia, 2290
Actively Recruiting
83
Novartis Investigative Site
Tiwi, Northern Territory, Australia, 810
Actively Recruiting
84
Novartis Investigative Site
Clayton, Victoria, Australia, 3168
Actively Recruiting
85
Novartis Investigative Site
East Melbourne, Victoria, Australia, 3002
Actively Recruiting
86
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil, 40170-110
Actively Recruiting
87
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil, 41825-010
Actively Recruiting
88
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil, 90470-340
Actively Recruiting
89
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil, 90560-032
Actively Recruiting
90
Novartis Investigative Site
São Paulo, São Paulo, Brazil, 05652-000
Actively Recruiting
91
Novartis Investigative Site
São Paulo, Brazil, 04501 000
Actively Recruiting
92
Novartis Investigative Site
Victoria, British Columbia, Canada, V8R 6V5
Actively Recruiting
93
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Actively Recruiting
94
Novartis Investigative Site
Oakville, Ontario, Canada, L6M1M1
Actively Recruiting
95
Novartis Investigative Site
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
96
Novartis Investigative Site
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
97
Novartis Investigative Site
Montreal, Quebec, Canada, H2X 0A9
Actively Recruiting
98
Novartis Investigative Site
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
99
Novartis Investigative Site
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
100
Novartis Investigative Site
Québec, Quebec, Canada, G1S 4L8
Actively Recruiting
101
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada, S7N 4H4
Actively Recruiting
102
Novartis Investigative Site
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
103
Novartis Investigative Site
Guangzhou, Guangdong, China, 510080
Actively Recruiting
104
Novartis Investigative Site
Harbin, Heilongjiang, China, 150081
Actively Recruiting
105
Novartis Investigative Site
Zhengzhou, Henan, China, 450003
Actively Recruiting
106
Novartis Investigative Site
Zhengzhou, Henan, China, 450008
Actively Recruiting
107
Novartis Investigative Site
Nanjing, Jiangsu, China, 210029
Actively Recruiting
108
Novartis Investigative Site
Nanchang, Jiangxi, China, 330009
Actively Recruiting
109
Novartis Investigative Site
Changchun, Jilin, China, 130021
Actively Recruiting
110
Novartis Investigative Site
Jinan, Shandong, China, 250021
Actively Recruiting
111
Novartis Investigative Site
Jinan, Shandong, China, 250117
Actively Recruiting
112
Novartis Investigative Site
Jining, Shandong, China, 272000
Actively Recruiting
113
Novartis Investigative Site
Chengdu, Sichuan, China, 610041
Actively Recruiting
114
Novartis Investigative Site
Chengdu, Sichuan, China, 610072
Actively Recruiting
115
Novartis Investigative Site
Ürümqi, Xinjiang, China, 830000
Actively Recruiting
116
Novartis Investigative Site
Hangzhou, Zhejiang, China, 310006
Actively Recruiting
117
Novartis Investigative Site
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
118
Novartis Investigative Site
Wenzhou, Zhejiang, China, 325000
Actively Recruiting
119
Novartis Investigative Site
Beijing, China, 100039
Actively Recruiting
120
Novartis Investigative Site
Beijing, China, 100730
Actively Recruiting
121
Novartis Investigative Site
Guangzhou, China, 510060
Actively Recruiting
122
Novartis Investigative Site
Qingdao, China, 266000
Actively Recruiting
123
Novartis Investigative Site
Shanghai, China, 200032
Actively Recruiting
124
Novartis Investigative Site
Shijiazhuang, China, 050035
Actively Recruiting
125
Novartis Investigative Site
Tianjin, China, 300480
Actively Recruiting
126
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106
Actively Recruiting
127
Novartis Investigative Site
Munich, Bavaria, Germany, 81377
Actively Recruiting
128
Novartis Investigative Site
Regensburg, Bavaria, Germany, 93053
Actively Recruiting
129
Novartis Investigative Site
Weiden in Der Oberpfalz, Bavaria, Germany, 92637
Actively Recruiting
130
Novartis Investigative Site
Langen, Hesse, Germany, 63225
Actively Recruiting
131
Novartis Investigative Site
Hildesheim, Lower Saxony, Germany, 31134
Withdrawn
132
Novartis Investigative Site
Bergisch Gladbach, North Rhine-Westphalia, Germany, 51465
Actively Recruiting
133
Novartis Investigative Site
Bielefeld, North Rhine-Westphalia, Germany, 33604
Withdrawn
134
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany, 40225
Withdrawn
135
Novartis Investigative Site
Essen, North Rhine-Westphalia, Germany, 45136
Actively Recruiting
136
Novartis Investigative Site
Mönchengladbach, North Rhine-Westphalia, Germany, 41061
Actively Recruiting
137
Novartis Investigative Site
Velbert, North Rhine-Westphalia, Germany, 42551
Actively Recruiting
138
Novartis Investigative Site
Dresden, Saxony, Germany, 01307
Actively Recruiting
139
Novartis Investigative Site
Lübeck, Schleswig-Holstein, Germany, 23563
Withdrawn
140
Novartis Investigative Site
Augsburg, Germany, 86150
Actively Recruiting
141
Novartis Investigative Site
Augsburg, Germany, 86179
Actively Recruiting
142
Novartis Investigative Site
Berlin, Germany, 10967
Actively Recruiting
143
Novartis Investigative Site
Berlin, Germany, 13125
Actively Recruiting
144
Novartis Investigative Site
Bottrop, Germany, 46236
Actively Recruiting
145
Novartis Investigative Site
Böblingen, Germany, 71032
Withdrawn
146
Novartis Investigative Site
Dessau, Germany, 06847
Actively Recruiting
147
Novartis Investigative Site
Erlangen, Germany, 91054
Actively Recruiting
148
Novartis Investigative Site
Essen, Germany, 45147
Actively Recruiting
149
Novartis Investigative Site
Hamburg, Germany, 20246
Withdrawn
150
Novartis Investigative Site
Kiel, Germany, 24105
Actively Recruiting
151
Novartis Investigative Site
Leipzig, Germany, 04277
Actively Recruiting
152
Novartis Investigative Site
Mainz, Germany, 55131
Withdrawn
153
Novartis Investigative Site
München, Germany, 80637
Actively Recruiting
154
Novartis Investigative Site
Ravensburg, Germany, 88214
Actively Recruiting
155
Novartis Investigative Site
Hong Kong, Hong Kong, 999077
Actively Recruiting
156
Novartis Investigative Site
Kowloon, Hong Kong, 999077
Actively Recruiting
157
Novartis Investigative Site
Tuenmen, Hong Kong, 999077
Actively Recruiting
158
Novartis Investigative Site
Hyderabad, Andhra Pradesh, India, 500034
Active, Not Recruiting
159
Novartis Investigative Site
Bangalore, Karnataka, India, 560017
Active, Not Recruiting
160
Novartis Investigative Site
Mumbai, Maharashtra, India, 400 012
Active, Not Recruiting
161
Novartis Investigative Site
Pune, Maharasthra, India, 411028
Active, Not Recruiting
162
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India, 110029
Active, Not Recruiting
163
Novartis Investigative Site
Bhubaneswar, Odisha, India, 751007
Active, Not Recruiting
164
Novartis Investigative Site
Chennai, Tamil Nadu, India, 600 035
Active, Not Recruiting
165
Novartis Investigative Site
Kolkata, West Bengal, India, 700054
Active, Not Recruiting
166
Novartis Investigative Site
Ahmedabad, India, 380054
Active, Not Recruiting
167
Novartis Investigative Site
Beersheba, Israel, 8457108
Actively Recruiting
168
Novartis Investigative Site
Petah Tikva, Israel, 4941492
Actively Recruiting
169
Novartis Investigative Site
Ramat Gan, Israel, 5265601
Actively Recruiting
170
Novartis Investigative Site
Tel Aviv, Israel, 6423906
Actively Recruiting
171
Novartis Investigative Site
Alc Cuahutemoc, Mexico City, Mexico, 06720
Actively Recruiting
172
Novartis Investigative Site
Tlalpan, Mexico City, Mexico, 14080
Actively Recruiting
173
Novartis Investigative Site
Monterrey, Nuevo León, Mexico, 64460
Actively Recruiting
174
Novartis Investigative Site
Coimbra, Portugal, 3000-075
Actively Recruiting
175
Novartis Investigative Site
Lisbon, Portugal, 1400-038
Actively Recruiting
176
Novartis Investigative Site
Lisbon, Portugal, 1649-035
Actively Recruiting
177
Novartis Investigative Site
Porto, Portugal, 4100-180
Actively Recruiting
178
Novartis Investigative Site
Porto, Portugal, 4200 319
Actively Recruiting
179
Novartis Investigative Site
Porto, Portugal, 4200-072
Actively Recruiting
180
Pan Oncology
Rio Piedras, Puerto Rico, 00935
Actively Recruiting
181
Novartis Investigative Site
Bundang Gu, Gyeonggi-do, South Korea, 13620
Actively Recruiting
182
Novartis Investigative Site
Gyeonggi-do, Korea, South Korea, 10408
Actively Recruiting
183
Novartis Investigative Site
Incheon, Korea, South Korea, 405 760
Actively Recruiting
184
Novartis Investigative Site
Seoul, Korea, South Korea, 02841
Actively Recruiting
185
Novartis Investigative Site
Seoul, Yangcheon Gu, South Korea, 07985
Actively Recruiting
186
Novartis Investigative Site
Seongnam Gyeonggi, South Korea, 463-712
Actively Recruiting
187
Novartis Investigative Site
Seoul, South Korea, 03080
Actively Recruiting
188
Novartis Investigative Site
Seoul, South Korea, 03722
Actively Recruiting
189
Novartis Investigative Site
Seoul, South Korea, 05505
Actively Recruiting
190
Novartis Investigative Site
Seoul, South Korea, 06273
Actively Recruiting
191
Novartis Investigative Site
Seoul, South Korea, 06351
Actively Recruiting
192
Novartis Investigative Site
Seoul, South Korea, 06591
Actively Recruiting
193
Novartis Investigative Site
Hualien City, Taiwan, 970
Actively Recruiting
194
Novartis Investigative Site
Kaohsiung City, Taiwan, 80756
Actively Recruiting
195
Novartis Investigative Site
Tainan, Taiwan, 71004
Actively Recruiting
196
Novartis Investigative Site
Taipei, Taiwan, 10002
Actively Recruiting
197
Novartis Investigative Site
Taipei, Taiwan, 114
Actively Recruiting
198
Novartis Investigative Site
Sakarya, Adapazari, Turkey (Türkiye), 54290
Actively Recruiting
199
Novartis Investigative Site
Ankara, Bilkent-Cankaya, Turkey (Türkiye), 06800
Actively Recruiting
200
Novartis Investigative Site
Istanbul, Fatih, Turkey (Türkiye), 34098
Actively Recruiting
201
Novartis Investigative Site
Istanbul, Kadikoy, Turkey (Türkiye), 34722
Actively Recruiting
202
Novartis Investigative Site
Izmir, Karsiyaka, Turkey (Türkiye), 35575
Actively Recruiting
203
Novartis Investigative Site
Denizli, Kinikli, Turkey (Türkiye), 20070
Actively Recruiting
204
Novartis Investigative Site
Antalya, Konyaalti, Turkey (Türkiye), 07070
Actively Recruiting
205
Novartis Investigative Site
Istanbul, Sariyer, Turkey (Türkiye), 34457
Actively Recruiting
206
Novartis Investigative Site
Ankara, Sihhiye-Altindag, Turkey (Türkiye), 06230
Actively Recruiting
207
Novartis Investigative Site
Diyarbakır, Sur, Turkey (Türkiye), 21280
Actively Recruiting
208
Novartis Investigative Site
Istanbul, Uskudar, Turkey (Türkiye), 34662
Actively Recruiting
209
Novartis Investigative Site
Ankara, Yenimahalle, Turkey (Türkiye), 06200
Actively Recruiting
210
Novartis Investigative Site
Ankara, Yenimahalle, Turkey (Türkiye), 06500
Actively Recruiting
211
Novartis Investigative Site
Adana, Yuregir, Turkey (Türkiye), 01230
Actively Recruiting
212
Novartis Investigative Site
Ankara, Turkey (Türkiye), 06520
Actively Recruiting
213
Novartis Investigative Site
Istanbul, Turkey (Türkiye), 34147
Actively Recruiting
214
Novartis Investigative Site
Izmir, Turkey (Türkiye), 35100
Actively Recruiting
215
Novartis Investigative Site
Kecioren Ankara, Turkey (Türkiye), 06010
Actively Recruiting
216
Novartis Investigative Site
Konya, Turkey (Türkiye), 42080
Actively Recruiting
217
Novartis Investigative Site
Samsun, Turkey (Türkiye), 55200
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here